Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | -5.49% |
|
-9.68% | +10.89% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
May. 14 | Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.89% | 73.04M | |
+18.94% | 125B | |
+13.86% | 108B | |
-7.37% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-14.04% | 16.37B | |
+1.87% | 13.58B | |
+27.77% | 11.66B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Citigroup Adjusts Price Target on Passage Bio to $5 From $7, Maintains Buy Rating